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Longitudinal Changes in Bone Mineral Content (BMC) in a cohort 
children and adolescents with CF 
J. Lowdon, I.J.M. Doul l  
CF Unit, The ChiMren's Centre, The ChiMren's Hospital of Wales, Cardiff, UK 
Aim:  To review longitudinal bone mineral density. 
Methods:  Review of all children and adolescents attending the UHW regional CF 
centre who have undergone at last 2 measurements of bone densitometry in the last 
5 years. 
Subjects: Twenty subjects (10 m) of mean age 10.9 years (SD 3.2) at initial 
assessment were reassessed at 2.2 years later. 3 subjects were receiving oral 
cot ticoister oids. 
Results: At  baseline mean weight SDS 0.4 (SD1.1), height SDS 0.4 (SD 1.1), BMI  
SDS 0.6 (1.1), FEVI% predicted 82% (SD 5), FVC 84% (SD 4) mad Shwachman 
Score 81 (SD 4). Over the 2.2 years, total hip BMC SDS improved from 0.5 (1.23) 
to 0.22 (1.38) and mean BMC lumbar spine SDS improved from 0.33 (1.15) to 
0.23 (1.18). Analyses of the 17 in the non steroid group who have had a second 
scan show the mean (SD) BMC total hip SDS has improved from 0.49 (1.33) to 
0.17 (0.54) mad mean BMC lumbar spine SDS has improved from 0.14 (1.13) to 
0.03 (0.62). For the 3 treated with oral cot ticosteroids, mean BMC total hip SDS 
has improved from 0.54 (0.39) to 0.92 (0.19) and BMC lumbar spine SDS has 
improved from 1.44 (0.33) to 0.50 (0.54). 
Conclusion: BMC total hip score increased significantly but not for lumbar spine 
over a mean of 2.2 years. 
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Serum zinc concenkaSon at diagnosis of cysSc fibrosis (CF) and one 
year later 
S. Van Biervl iet 1,J.P. Van Biervl iet ~, E. Robberecht 1 
~CF center Ghent, 2department paediatrics Bruges, Belgium 
Aim:  There is no consensus whether zinc (Zaa) supplementation is necessary in CE 
Serum Zaa concentration is far from the ideal method but is the only easy available. 
Further, the control values are problematic since Zn  concentrations vary with age 
and populations. Since we have described a control population earl ier (1), it was 
possible to compare our CF patients with our normal population. 
Methods:  A blood sample for serum Zinc determination was taken in all new 
diagnosed CF patients (1998 2CO3). A year later at the annual controls, a second 
sample was taken. Data concerning pancreatic insufficiency, zinc supplementation 
and genotype were collected. 
Results: 32 patients (20 boys) with a mean age of 1,35y (0 12,5 y) were included 
ha the study. 8 children were older than 1 y at diagnosis. The mean Zn concentration 
at diagnosis was 10,9 ~tmol/L (5 21,4), with a significant increase one year later 
(mean: 12,38 ~tmol/L (7,803 16,1)) (p~),01). There was no difference in Zn 
concentration depending on gender, genotype or pancreatic function (sufficient 
n 6). Six patients with Zn supplementation had the same evolution as the others. 
Compared to age matched healthy controls, there is no significant difference ha 
serum Zn concentration either at diagnosis or one year later, although the patients 
with delayed iagnosis (>1 y) tend to have lower serum Zn than thek pears (n.s.). 
Conclusion: Although it was demonstrated that steatorrhcea c uses Zn loss, the serum 
Zn concentration is not sensitive nough to detect it. Based on the serum Zn 
concentration of CF patients we have no arguments for supplementation. Zn 
concentrations improve with therapy, however the effect is due to the age related 
changes of Zn concentration i  children, i 1. Biol. trace Elem. Res. 2CO1 ; 79:115 120) 
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Fatty acids in cystic fibrosis 
W. Petchey 1, A.L. Cawood 1, M.P. Carroll 2, J.L. Murphy 1, S.A. Woott on 1 
~Institute ofHuman Nutrition, 2Department of Respiratory Medicine, Southampton 
University, Southampton, ~ZK. 
Aim It has long been known that CF patients exhibit alterations in the fatty acid 
composition of plasma. However, the rmlge of divet~;ence is broad mid most studies 
have reported on plasma phospholipids. ~ne aim of tiffs study was to investigate fatty 
acid tn o files in four lipid classes. 
Method Fasted blood samples were obtained fiom 19 patients with CF mid 10 controls 
(C). Plasma was sepm ated by centrifugation, lipid extracted, mid sepm ated hlto fiactions 
by solid phase extraction. Fatty acids were methylated mid mlalysed by GC PID. 
Results A large numbei of fatty acids were identified in each lipid fiaction; 
phospholipid (PC), non esterified fatty acid (NEFA), t i i  acyl glycerol (TAG), mid 
cholesterol ester (CE) (table 1). Total n 6 PUPA content was lower in CF patients for 
each lipid fi action. In pmticular linoleic acid (LA; 18:2n 6) was lower ha patients with 
CF in each lipid fiaction. However machidonic acid (AA; 20:4n 6) was not different 
between the groups. Total n 3 PUPA content was lower in the PC mid TAG fl action of 
the CF patients compared to controls. In the CF patients ALNA (18:3n 3) was increased 
ha PC and CE, DHA (22:6n 3) was low ha all fiactions, but EPA (20:5n 3) mid DPA 
(22:5n 3) only showed significmlt differences in the TAG fiaction. 
Tabl~ 1: Mean percentage of fatty acid in e h fraction 
% of fatty acid in each fraction 
PC CE NEFA TAG 
CF C CF C CF C CF C 
LA 220* 259 495* 586 115" 152 145" 207 
AA 87 92 56 55 18 19 14 16 
ALNA 013" 005 126" 060 0 0 039 028 
EPA 084 085 055 072 017 022 019" 034 
DPA 084 082 0 0 033 034 021" 038 
DHA 214" 387 045* 087 062* 097 030* 081 
* Sig diff flora C; P<005 
Cozwlusion It appears that patients with CF have an alter ed n 3 and n 6 PUPA profile 
compared to controls. Low concentt ations of LA and DHA were evident in all fi actions, 
but not ALNA, EPA, mid DPA, indicative of a constraint in DHA synfllesis. 
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Cochrane systematic review of omega-3 fatty acids (from fish oils) for 
cystic fibrosis 
N. Beckles Wil lson 1, T. Ell iott 2, M. Ever ard 3 
~Department of Nutrition & Dietetics, 2Department of Research a~u] Development, 
3D epartrnent of Paediatrics, SheffeM Children's NHS Trust, Sheffield, UK 
Background:  A diet r ich in omega 3 essential fatty acids (derived from fish oil) 
may have beneficial anti hfflammatory effects for cbronic medical conditions uch 
as Cystic Fibrosis. 
A im:  Is there evidence that omega 3 essential fatty acid supplementation reduces 
morbidity mad mortality? I f  so are there any associated adverse events? 
Methods:  
Search strategy Comprehensive electronic database searches plus hand searching 
conference prceeedings. 
Selection er l te r la  Randomised controlled trials (RCI's) ha patients with cystic 
fibrosis in which omega 3 fatty acid supplements were compared with placebo. 
Data  collection & aimlysls Two reviewers independently selected the trials for 
inclusion, assessed methodological quality and extracted ata. There were no 
common outcomes, so only qualitative analysis was undertaken. 
Ma in  results: Six trials were identified, but only two (n 31) met the inclusion 
criteria. Both compared omega 3 oils with olive oil controls for a 6 week  treatment 
period. One study (n 19) showed improved lung function tests mad lower sputum 
volume. Both studies reported that diardaoea was a problem for some participants 
(for both fish oil and olive oil control groups) and that this was resolved by 
increasing the dosage of pancreatic enzy me supplements. 
Rev iewers  conduslons:  There is insufficient evidence for the safety mad 
effectiveness of omega 3 fatty acids in cystic fibrosis. A large, long term multi  
centre RCq" is needed to determine i f there is a significant therapeutic effect and to 
assess the ilffluence of disease severity, dosage mad treatment duration. 
